Skip to main content
Clinical Trials/NCT05441878
NCT05441878
Unknown
Phase 4

To Compare 20% Albumin vs. Balanced Salt Solution as Resuscitation Fluid and Identify Fluid Responsiveness Criteria in Critically Ill Patients With Cirrhosis With Sepsis Induced Hypotension; a Prospective Randomized Controlled Trial.

Post Graduate Institute of Medical Education and Research, Chandigarh1 site in 1 country150 target enrollmentAugust 15, 2020

Overview

Phase
Phase 4
Intervention
Balanced salt solution
Conditions
Cirrhosis, Liver
Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Enrollment
150
Locations
1
Primary Endpoint
To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess new onset of hepatorenal syndrome (HRS) or acute kidney injury (AKI)
Last Updated
3 years ago

Overview

Brief Summary

Patients with cirrhosis patients have a high incidence of sepsis which can trigger decompensation and may result in prolonged hospital stay and increased mortality. About 30%-50% admissions of patients with cirrhosis have sepsis at presentation and about 15% patients admitted to hospital develop sepsis during the hospital stay . After infection develops, the patient may develop acute kidney injury (AKI), shock, encephalopathy or disseminated intravascular coagulation (DIC) further decreasing the chances of survival. In fact, sepsis in patients with cirrhosis is associated with 15% in-hospital mortality, approximately double that of patients without sepsis. So, sepsis is directly responsible for 30-50% of deaths in cirrhosis . Therefore, it is critical to manage sepsis early and appropriately in cirrhosis to reduce the complications and mortality. Early administration of fluids, source control and empirical antibiotics along with vasopressors if refractory shock are essential components of treatment in all patients with sepsis. Currently, the most accepted strategy for early sepsis management is a combination of early goal directed therapy (EGDT) and physiological parameters, such as urine output, lactate clearance, and administration of antibiotics, within 1 hour of presentation . The use of central venous pressure assessment is fallacious for gauging adequacy of fluid resuscitation in cirrhosis, and the difficulty of performing echocardiographic assessments in the setting of ascites and cirrhotic cardiomyopathy is also well described .

Registry
clinicaltrials.gov
Start Date
August 15, 2020
End Date
December 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Responsible Party
Principal Investigator
Principal Investigator

Madhumita Premkumar

Assistant professor, Department of Hepatology

Post Graduate Institute of Medical Education and Research, Chandigarh

Eligibility Criteria

Inclusion Criteria

  • Clinical/Imaging or Biopsy proven liver cirrhosis of any etiology who consent for enrolment.
  • Hypotension (Mean arterial pressure \<65mmHg or Systolic blood pressure \<90mmHg)
  • Aged between18-65 yrs

Exclusion Criteria

  • Already received colloid or more than 2 litres of fluid without baseline echocardiographic assessment.
  • Already on vasopressors/inotropes
  • Severe pre-existing cardiopulmonary disease
  • Acute Respiratory Distress Syndrome (ARDS)
  • Active bleeding like variceal bleed
  • Cerebrovascular events
  • Chronic renal disease - End Stage Renal Disease (ESRD)/ patient on renal replacement therapy
  • Admission to ICU following liver transplantation, burns, cardiac surgery
  • Brain death or likely brain death within 24 hours
  • Previous adverse reaction to human albumin solution

Arms & Interventions

20% Albumin arm

20% Albumin in a dose of 20-40 gm per day as infusion over 12-24 h

Intervention: Balanced salt solution

20% Albumin arm

20% Albumin in a dose of 20-40 gm per day as infusion over 12-24 h

Intervention: 20% albumin

Balanced salt solution arm

Fluid resuscitation protocol includes use of an immediate 500 ml bolus of crystalloid i.e., balanced salt solution (BSS) or 0.9% normal saline (Rescue phase), followed by 20 ml/kg fluid in the first 6 hours titrated to target MAP of \> 65mmHg.The second phase of fluid resuscitation (Optimization phase) will be performed as per IVC targets, attainment of lactate clearance, and LUS score to prevent overload.

Intervention: Balanced salt solution

Outcomes

Primary Outcomes

To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess new onset of hepatorenal syndrome (HRS) or acute kidney injury (AKI)

Time Frame: At 48 hours.

To compare the new onset of hepatorenal syndrome (HRS) or acute kidney injury (AKI)in patients with cirrhosis and sepsis induced hypotension

To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess IVC dynamics.

Time Frame: At 48 hours.

To compare the IVC dynamics in patients with cirrhosis and sepsis induced hypotension

To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess dynamic changes in cardiac output, stroke volume and E/e' echocardiographic parameters.

Time Frame: At 48 hours.

To compare the cardiac output in patients with cirrhosis and sepsis induced hypotension

Secondary Outcomes

  • Urinary marker of AKI (NGal)(At enrolment)
  • Change in urinary markers of AKI (NGal)(At 24 hours.)
  • Change in urinary markers of AKI(NGal)(At 48 hours.)
  • To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension., and assess vasopressor requirement(At 24 hours)

Study Sites (1)

Loading locations...

Similar Trials